AbbVie is acquiring Capstan Therapeutics, a startup with technology that enables in vivo engineering of immune cells.

AbbVie said on Monday it would acquire privately held cell therapy developer Capstan Therapeutics in a deal worth up to $2.1 ...

An engineered protein turns off the kind of immune cells most likely to damage tissue as part of type 1 diabetes, hepatitis ...

AbbVie's $2.1 billion Capstan deal brings a novel in-vivo CAR-T therapy and tLNP platform to boost its immunology pipeline.

AbbVie has agreed to buy Capstan Therapeutics for up to $2.1 billion, expanding its pipeline with a potential first-in-class ...

In the fight against cancer, immunotherapy—which aims to boost the body's natural defenses against cancer—is experiencing ...

LJI scientists have discovered that T cells may help detect Parkinson's disease years before motor symptoms appear. Your T ...

Your T cells work hard to fight disease. Unfortunately, "friendly fire" from T cells can sometimes harm the body's healthy ...

Systemic sclerosis (SSc) or scleroderma is a rare, chronic, autoimmune disorder that hardens connective tissue and muscle in ...

Scientists have discovered a stealthy mechanism that cytomegalovirus (CMV)—the leading infectious cause of birth defects in ...

Advanced imaging technologies are uncovering surprising roles for CD8+ T cells—not just in immune defense, but also in supporting tissue repair and regeneration.

In the fight against cancer, immunotherapy - which aims to boost the body's natural defences against cancer - is experiencing remarkable growth. Most of these treatments are based on CD8 T lymphocytes ...